IPO - MUSTANG BIO, INC.

Form Type: 424B4

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: New

Accession Number: 000141057825000085

Filing Summary: Mustang Bio, Inc. has filed a prospectus for the offering of up to 495,000 shares of its common stock and related warrants, including Series C-1 and Series C-2 Warrants, alongside pre-funded warrants to allow certain investors to acquire additional shares while preventing ownership from exceeding 4.99% or 9.99%. The public offering price for shares combined with the warrants is set at $3.01, and the pre-funded warrants come with an exercise price of $0.0001 per share. The offering is expected to close around February 7, 2025, and will terminate on March 5, 2025, unless withdrawn earlier. The company aims to utilize the proceeds primarily for its clinical trials and research in CAR T therapies targeting various cancers. Notably, it had a reverse stock split on January 15, 2025, at a ratio of 1-for-50 to comply with Nasdaq listing requirements. The filing clarifies there is no intended trading market for the pre-funded warrants or accompanying warrants, impacting their liquidity. It also describes potential risks in the offering and the implications of being a smaller reporting company, while reaffirming its commitment to addressing compliance issues with Nasdaq.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-02-05

Corporate Action: Ipo

Type: New

Accession Number: 000110465925009409

Filing Summary: Mustang Bio, Inc. requests the Securities and Exchange Commission to accelerate the effective date of its Registration Statement on Form S-1 (Reg. No. 333-284299) to February 5, 2025, at 5:15 p.m. Eastern time, or as soon as practicable thereafter. The request was made pursuant to Rule 461 under the Securities Act of 1933. The Company authorizes attorneys Rakesh Gopalan and Alexander Yarbrough to orally modify or withdraw this request for acceleration. Confirmation of the effective date should be communicated to Mr. Gopalan or Mr. Yarbrough once the Registration Statement is declared effective.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-05

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925009408

Filing Summary: On February 5, 2025, Mustang Bio, Inc. filed an amendment to its initial registration statement on Form S-1, aiming to provide updates regarding its ongoing plans for registering the sale of its equity securities. This filing highlights the company's commitment to pursuing an initial public offering. It outlines the details concerning the types and amounts of securities to be offered, as well as the intended use of proceeds from the offering primarily for research and development, working capital, and general corporate purposes. Furthermore, references are made to previous authorized offerings and disclosures on registration statements, detailing Mustang Bio's interactions with related entities such as Fortress Biotech, Inc. The filing indicates a readiness to proceed with the offering contingent upon market conditions and investor interest.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-15

Corporate Action: Ipo

Type: New

Accession Number: 000141057825000028

Filing Summary: On January 15, 2025, Mustang Bio, Inc. filed its S-1 registration statement with the SEC to register new shares as part of its Initial Public Offering (IPO). The company aims to raise capital through the offering to fund ongoing research and development projects, operational expenses, and to strengthen its financial position. The offering will include various classes of Common Stock and associated securities such as Preferred Stock and Warrants. The net proceeds from the offering are intended to support clinical trials, expand manufacturing capabilities, and pursue partnerships within the biotechnology sector. Mustang Bio also disclosed its intention to utilize a portion of the funds raised for general corporate purposes, including potential acquisitions and investments in new technologies.

Document Link: View Document